ViCentra Raises $13M To Boost Growth And Develop Next-Gen Insulin System

The latest investment includes new capital from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech, along with increased backing from existing investor Innovation Industries.

ViCentra develops and manufactures Kaleido, a compact and discreet alternative to traditional insulin pumps designed to support diabetes management. Positioned as the smallest, lightest and most precise insulin patch pump in its category, Kaleido delivers automated insulin therapy through integration with Diabeloop’s clinically validated hybrid closed-loop algorithms, DBLG1 and DBLG2.

Read Also - French Biotech Spore.Bio Raises Google.org Funding, Launches AI Research Unit

Designed to look and feel more like personal technology than a conventional medical device Kaleido combines advanced functionality with thoughtful industrial design. Made from premium materials, it features customisable aluminium shells available in ten colour options, allowing users flexibility in how and where the pump is worn while supporting everyday therapy needs.

The latest funding follows the $85 million raised in September 2025. Commenting on the investment CEO Tom Arnold said the past year represented a period of strong progress for the company, noting that the new capital will be used to expand manufacturing capabilities and strengthen commercial operations and customer support.

Our goal for 2026 is clear: convert strong demand into satisfied users through uncompromising quality and performance, and nearly triple our European user base by the end of 2026.

With this funding, ViCentra plans to scale up manufacturing, strengthen commercial operations in Germany, the Netherlands, and France and accelerate preparations to launch its next-generation Kaleido system in the U.S., positioning the company for continued growth in the insulin delivery market.

About ViCentra

ViCentra, based in Utrecht, Netherlands develops the Kaleido insulin patch pump, a discreet, flexible and elegantly designed alternative to traditional insulin pumps. Focused on innovation and user-centric design, the company is expanding across Europe and preparing for U.S. entry, backed by investors including Innovation Industries, EQT Life Sciences, and ROM Utrecht Region.